Nippon Kayaku Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
84

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$600
CD-ROM Mail Delivery
$900
Hard Copy Mail Delivery
$900
Electronic Access - Multi-User License
$1200

“Nippon Kayaku - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Nippon Kayaku. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in phase-II. There are 10 cancer drugs by Nippon Kayaku which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Nippon Kayaku - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Nippon Kayaku

  1.1 Business Overview

  1.2 Nippon Kayaku Pipeline Overview

 

2. Nippon Kayaku Cancer Drugs in Phase-I

  2.1 NK 314

 

3. Nippon Kayaku Cancer Drugs in Phase-II

  3.1 Ozarelix

  3.2 NK 012

 

4. Nippon Kayaku Cancer drugs in Phase-III

  4.1 Paclitaxel Micelle Formulation - Nippon Kayaku/NanoCarrier

 

5. Nippon Kayaku Cancer Drugs in Preregistration

  5.1 Apaziquone

 

6. Nippon Kayaku Cancer Drugs in Registered

  6.1 Trastuzumab Biosimilar – Celltrion

 

7. Marketed Cancer Drugs by Nippon Kayaku

  7.1 Zoledronic Acid

  7.2 Lapatinib

  7.3 Ubenimex

  7.4 Topotecan

  7.5 Amrubicin

  7.6 Pamidronic Acid

  7.7 Toremifene

  7.8 Doxorubicin - Nippon Kayaku

  7.9 Cytarabine Ocfosfate

  7.10 Pirarubicin

 

 8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 Gusperimus

  8.2 NKS 01

  8.3 NK 611

  8.4 Colforsin

  8.5 Sebriplatin

  8.6 Liblomycin

  8.7 Diethylnorspermine

  8.8 NK 292

  8.9 NK 109

  8.10 FE 35A

  8.11 Heliquinomycin

  8.12 NK 374186A3

  8.13 NF 00659A3

  8.14 NF 00659B2

  8.15 NA 22598A1

  8.16 NF 00695B1

  8.17 NF 00659A1

  8.18 NF 00659A2

  8.19 Medelamine A

  8.20 Medelamine B

  8.21 NA 16887

  8.22 Woodfruticosin

Figure 1-1: Nippon Kayaku Cancer Pipeline by Phase (%)

Figure 1-2: Nippon Kayaku Cancer Pipeline by Phase (Number)